In this video, health-care analyst David Williamson discusses Dendreon's recent third-quarter results. He focuses on why, despite the positive trends, Dendreon is far from out of the woods. Watch and find out why investors who bid up shares as much as 30% intraday on Friday may be missing the bigger picture.
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Why Investors Should Be Concerned About Dendreon
Breaking down Dendreon's Q3 results.
David Williamson owns shares of Johnson & Johnson. Follow him on Twitter, @MotleyDavid. The Motley Fool owns shares of Dendreon and Johnson & Johnson. Motley Fool newsletter services recommend Johnson & Johnson. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned



*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.